

HEMOTAG

Portable, point-of-care left ventricular function diagnosis system

The Problem

- ❗ 4-8% of adults without prior symptoms are at risk of heart failure.¹
- ❗ 84% mortality in men and 77% in women² within 6 years after onset of heart failure.



92 million patients need cardiac evaluation.




6 million heart failure patients need routine monitoring to prevent adverse outcomes.



16 million develop heart failure with non-specific symptoms.

The Solution

HEMOTAG brings high-value hemodynamic assessment of cardiac pressure and function to primary and urgent care. The easy-to-use, wireless design allows accurate measurement of heart muscle performance. Sensor data is automatically sent to a HIPAA-compliant cloud and analyzed with machine-learning algorithms. Electronic patient reports are generated and made available to the care team within minutes.



HOW IT WORKS:




1. Patients with non-specific symptoms are evaluated in urgent or primary care settings. The device is easily and rapidly applied to the patient's chest.

30
SECONDS



2. With the patient resting, the HEMOTAG app initiates the assessment. An audible signal indicates the end of the process.

90
SECONDS



3. HEMOTAG's HIPAA-compliant cloud uses machine learning algorithms to analyze the data and generate an electronic report.

2
MINUTES



4. The physician reviews the HEMOTAG report and assesses if a referral to a cardiologist is indicated or if heart function is normal.

HEMOTAG saves lives by allowing faster, more detailed evaluation of cardiac function in patients with non-specific symptoms.

1. Echouffo-Tcheugui, J. B. et al. (2016). Assessing the risk of progression from asymptomatic left ventricular dysfunction to overt heart failure: a systematic overview and meta-analysis. *JACC: Heart Failure*, 4(4), 237-248.


2. Ho, K. K. et al. (1993). Survival after the onset of congestive heart failure in Framingham Heart Study subjects. *Circulation*, 88(1), 107-115.

The Opportunity

- Acquire measurement of LV function comparable to the gold standard echocardiogram
- Diagnose left ventricular dysfunction in primary and urgent care settings
- AI-driven, cloud-based algorithms automatically provide unambiguous diagnoses
- Empower non-cardiologists to triage heart disease accurately
- Reduce false-negative diagnoses, prevent unnecessary cardiac events

The Company

- \$7M SBIR grants (NIH, NSF, DARPA, US ARMY)
- 40 under 40 company
- 2018 & 2019 Defense Innovation Award
- 4 granted patent, 4 US filed and 2 International PCTs
- 400+ patient clinical validation and 15 abstract publications
- Established medical device contract manufacturing and quality management system
- FDA Class II 510(k) clearance expected in 2020



“Aventusoft’s technology has the opportunity to become an important tool for patients for home monitoring, pre-hospital caregivers as well as for emergency and inpatient bedside diagnosis and monitoring.”

Dr. Kenneth Schepcke

(Medical Director, EMS, Palm Beach County, FL)

“Love the simple design. So much easier than the ECG monitor.”

Marcia Garcia

(Physician Assistant, Florida Cardiology Clinic, Atlantis, FL)

EXECUTIVE TEAM:



Kaustubh Kale

Founder & CEO

National Minority Health 40 under 40, S. Florida 40 Under 40, Becker’s Healthcare Rising star leader under 40, U. Florida highest Award for Leadership, 5 Patents, 10 yrs exp. at Motorola Inc generating multi-million in revenue



Zaffer Merchant

Chief Product Officer

26+ yrs product development experience at Motorola Inc, 5+ yrs Director Handset Engineering at Nextel International, Motorola Fellow and Innovator with 22 Patents



Steven Borzak, MD, FACC

Principal Investigator for Clinical Studies

27 yrs Cardiology exp., Harvard Medical School, Brigham’s and Women’s Hospital, Henry Ford, University of Miami, JFK hospital, over 100 publications

HEMOTAG

info@HEMOTAG.com | www.HEMOTAG.com

Caution - Investigational Device, Limited by Federal Law to Investigational Use. Not available for commercial use.

Patent No: US 10165985 B2, Patent No: US 8475396 B2, Patent No: US 10531839 B2, Patent No: US 2017/0199962 A1, Patents pending.

HEMOTAG is a registered trademark by Aventusoft, Florida. F15-01-08 HemoTag Fact Sheet - General Rev C